COAG
Hemab Therapeutics Holdings, Inc.
Price Chart
Latest Quote
$49.29
+4.76 (+10.69%)
Current Price
| Previous Close | $44.53 |
| Open | $44.50 |
| Day High | $50.11 |
| Day Low | $43.26 |
| Volume | 318,407 |
Stock Information
| Shares Outstanding | 46.71M |
| Total Debt | $1.06M |
| Cash Equivalents | $163.53M |
| Net Income | $-71.29M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $2.30B |
| EPS (TTM) | $-10.13 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $2.50B |
| Income | $-71.29M |
| Book/sh | $-209.96 |
| Cash/sh | $3.50 |
| Employees | 59 |
Financial Ratios
| Quick Ratio | 12.51 |
| Current Ratio | 12.85 |
| Debt/Eq | 0.66 |
Returns & Margins
Ownership
| Insider Ownership | 10.78% |
| Institutional Ownership | 65.89% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -19.61 |
| P/B | -0.23 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $50.00 |
Technical Indicators
| SMA20 | $35.32 |
| SMA50 | $30.02 |
| RSI | 77.79 |
| ATR | 4.2593 |
| Shares Float | 23.74M |
| Short Ratio | 5.74 |
| Rel Volume | 0.87 |
Performance History
| Week | +29.61% |
| Month | +93.22% |
| YTD | +44.97% |
| 10 Years | +44.97% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-07-17 | $49.29 | 320,000 |
| 2026-07-16 | $44.53 | 394,000 |
| 2026-07-15 | $43.32 | 307,400 |
| 2026-07-14 | $43.31 | 323,800 |
| 2026-07-13 | $39.51 | 369,700 |
| 2026-07-10 | $38.03 | 210,400 |
| 2026-07-09 | $37.20 | 313,400 |
| 2026-07-08 | $33.89 | 347,100 |
| 2026-07-07 | $31.49 | 162,000 |
| 2026-07-06 | $29.97 | 618,100 |
| 2026-07-02 | $31.00 | 251,800 |
| 2026-07-01 | $32.50 | 228,800 |
| 2026-06-30 | $36.73 | 321,600 |
| 2026-06-29 | $36.73 | 362,200 |
| 2026-06-26 | $32.37 | 329,200 |
| 2026-06-25 | $27.72 | 126,400 |
| 2026-06-24 | $28.76 | 135,000 |
| 2026-06-23 | $29.15 | 347,900 |
| 2026-06-22 | $31.74 | 355,800 |
| 2026-06-18 | $29.24 | 1,548,100 |
About Hemab Therapeutics Holdings, Inc.
Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency; and second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand disease. It also advances multiple preclinical and discovery-stage assets. The company was founded in 2020 and is based in Cambridge, Massachusetts.
đ° Latest News
Sector Update: Healthcare Stocks Advance Late Afternoon
MT Newswires âĸ 2026-07-13T19:34:41ZHemab Therapeutics Details Post-IPO Pipeline Push, Sutacimig Phase III Plans
MarketBeat âĸ 2026-06-09T03:03:51Z
Hemab Therapeutics IPO Debut Puts COAG And Pipeline Risks In Focus
Simply Wall St. âĸ 2026-05-03T07:07:46Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Revenue | ||
| Total Revenue | $0 | $0 |
| Operating Revenue | $0 | $0 |
| Expenses | ||
| Total Expenses | $70,119,000 | $50,383,000 |
| Other Income Expense | $4,005,000 | $-1,879,000 |
| Other Non Operating Income Expenses | $4,005,000 | $-1,879,000 |
| Net Non Operating Interest Income Expense | $1,974,000 | $3,740,000 |
| Operating Expense | $70,119,000 | $50,383,000 |
| General And Administrative Expense | $10,487,000 | $8,971,000 |
| Income & Earnings | ||
| Net Income From Continuing Operation Net Minority Interest | $-63,913,000 | $-48,707,000 |
| Net Interest Income | $1,974,000 | $3,740,000 |
| Interest Income | $1,974,000 | $3,740,000 |
| Normalized Income | $-63,913,000 | $-48,707,000 |
| Net Income From Continuing And Discontinued Operation | $-63,913,000 | $-48,707,000 |
| Total Operating Income As Reported | $-70,119,000 | $-50,383,000 |
| Net Income Common Stockholders | $-63,913,000 | $-48,707,000 |
| Net Income | $-63,913,000 | $-48,707,000 |
| Net Income Including Noncontrolling Interests | $-63,913,000 | $-48,707,000 |
| Net Income Continuous Operations | $-63,913,000 | $-48,707,000 |
| Pretax Income | $-64,140,000 | $-48,522,000 |
| Interest Income Non Operating | $1,974,000 | $3,740,000 |
| Operating Income | $-70,119,000 | $-50,383,000 |
| Per Share | ||
| Diluted EPS | $-2.33 | $-1.77 |
| Basic EPS | $-2.33 | $-1.77 |
| Other | ||
| Tax Effect Of Unusual Items | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-69,815,000 | $-50,135,000 |
| Reconciled Depreciation | $304,000 | $248,000 |
| EBITDA (Bullshit earnings) | $-69,815,000 | $-50,135,000 |
| EBIT | $-70,119,000 | $-50,383,000 |
| Diluted Average Shares | $27,442,910 | $27,442,910 |
| Basic Average Shares | $27,442,910 | $27,442,910 |
| Diluted NI Availto Com Stockholders | $-63,913,000 | $-48,707,000 |
| Tax Provision | $-227,000 | $185,000 |
| Research And Development | $59,632,000 | $41,412,000 |
| Selling General And Administration | $10,487,000 | $8,971,000 |
| Other Gand A | $6,078,000 | $4,978,000 |
| Salaries And Wages | $4,409,000 | $3,993,000 |
Fetched: 2026-07-15
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Assets | ||
| Net Tangible Assets | $-176,635,000 | $-115,273,000 |
| Total Assets | $194,783,000 | $96,278,000 |
| Total Non Current Assets | $2,232,000 | $3,043,000 |
| Other Non Current Assets | $531,000 | $476,000 |
| Current Assets | $192,551,000 | $93,235,000 |
| Prepaid Assets | $4,437,000 | $3,327,000 |
| Receivables | $2,629,000 | $1,583,000 |
| Other Receivables | $2,629,000 | $1,583,000 |
| Cash Cash Equivalents And Short Term Investments | $185,485,000 | $88,325,000 |
| Cash And Cash Equivalents | $87,974,000 | $74,407,000 |
| Debt | ||
| Total Debt | $1,220,000 | $1,725,000 |
| Long Term Debt And Capital Lease Obligation | $573,000 | $1,056,000 |
| Current Debt And Capital Lease Obligation | $647,000 | $669,000 |
| Liabilities | ||
| Total Liabilities Net Minority Interest | $371,418,000 | $211,551,000 |
| Total Non Current Liabilities Net Minority Interest | $360,741,000 | $204,866,000 |
| Current Liabilities | $10,677,000 | $6,685,000 |
| Payables And Accrued Expenses | $7,023,000 | $4,350,000 |
| Payables | $5,734,000 | $3,157,000 |
| Accounts Payable | $5,734,000 | $3,157,000 |
| Other Non Current Liabilities | - | $63,000 |
| Equity | ||
| Common Stock Equity | $-176,635,000 | $-115,273,000 |
| Total Equity Gross Minority Interest | $-176,635,000 | $-115,273,000 |
| Stockholders Equity | $-176,635,000 | $-115,273,000 |
| Gains Losses Not Affecting Retained Earnings | $175,000 | $-365,000 |
| Retained Earnings | $-181,858,000 | $-117,945,000 |
| Preferred Securities Outside Stock Equity | $360,168,000 | $203,747,000 |
| Other | ||
| Ordinary Shares Number | $44,192,910 | $44,192,910 |
| Share Issued | $44,192,910 | $44,192,910 |
| Tangible Book Value | $-176,635,000 | $-115,273,000 |
| Invested Capital | $-176,635,000 | $-115,273,000 |
| Working Capital | $181,874,000 | $86,550,000 |
| Capital Lease Obligations | $1,220,000 | $1,725,000 |
| Total Capitalization | $-176,635,000 | $-115,273,000 |
| Additional Paid In Capital | $4,916,000 | $2,905,000 |
| Capital Stock | $132,000 | $132,000 |
| Common Stock | $132,000 | $132,000 |
| Long Term Capital Lease Obligation | $573,000 | $1,056,000 |
| Current Capital Lease Obligation | $647,000 | $669,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $3,007,000 | $1,666,000 |
| Current Accrued Expenses | $1,289,000 | $1,193,000 |
| Net PPE | $1,701,000 | $2,567,000 |
| Accumulated Depreciation | $-723,000 | $-419,000 |
| Gross PPE | $2,424,000 | $2,986,000 |
| Leases | $82,000 | $82,000 |
| Other Properties | $775,000 | $775,000 |
| Machinery Furniture Equipment | $475,000 | $459,000 |
| Buildings And Improvements | $1,092,000 | $1,670,000 |
| Properties | $0 | $0 |
| Other Short Term Investments | $97,511,000 | $13,918,000 |
Fetched: 2026-07-15
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Free Cash Flow | ||
| Free Cash Flow | $-61,491,000 | $-45,874,000 |
| Operating Activities | ||
| Operating Cash Flow | $-61,475,000 | $-45,592,000 |
| Cash Flow From Continuing Operating Activities | $-61,475,000 | $-45,592,000 |
| Investing Activities | ||
| Capital Expenditure | $-16,000 | $-282,000 |
| Investing Cash Flow | $-81,482,000 | $61,903,000 |
| Cash Flow From Continuing Investing Activities | $-81,482,000 | $61,903,000 |
| Financing Activities | ||
| Issuance Of Capital Stock | $156,421,000 | $0 |
| Financing Cash Flow | $156,301,000 | $-100,000 |
| Cash Flow From Continuing Financing Activities | $156,301,000 | $-100,000 |
| Net Preferred Stock Issuance | $156,421,000 | $0 |
| Preferred Stock Issuance | $156,421,000 | $0 |
| Other | ||
| Repayment Of Debt | $-120,000 | $-100,000 |
| Interest Paid Supplemental Data | $10,000 | $18,000 |
| Income Tax Paid Supplemental Data | $172,000 | $88,000 |
| End Cash Position | $87,974,000 | $74,407,000 |
| Beginning Cash Position | $74,407,000 | $58,196,000 |
| Effect Of Exchange Rate Changes | $223,000 | $0 |
| Changes In Cash | $13,344,000 | $16,211,000 |
| Net Issuance Payments Of Debt | $-120,000 | $-100,000 |
| Net Long Term Debt Issuance | $-120,000 | $-100,000 |
| Long Term Debt Payments | $-120,000 | $-100,000 |
| Net Investment Purchase And Sale | $-81,466,000 | $62,185,000 |
| Sale Of Investment | $171,031,000 | $115,474,000 |
| Purchase Of Investment | $-252,497,000 | $-53,289,000 |
| Net PPE Purchase And Sale | $-16,000 | $-282,000 |
| Purchase Of PPE | $-16,000 | $-282,000 |
| Change In Working Capital | $1,355,000 | $1,447,000 |
| Change In Other Current Liabilities | $-522,000 | $-471,000 |
| Change In Other Current Assets | $-55,000 | $-9,000 |
| Change In Payables And Accrued Expense | $4,088,000 | $2,271,000 |
| Change In Accrued Expense | $1,511,000 | $1,360,000 |
| Change In Payable | $2,577,000 | $911,000 |
| Change In Account Payable | $2,577,000 | $911,000 |
| Change In Prepaid Assets | $-2,156,000 | $-344,000 |
| Other Non Cash Items | $-464,000 | $794,000 |
| Stock Based Compensation | $2,011,000 | $1,906,000 |
| Amortization Of Securities | $-768,000 | $-1,280,000 |
| Depreciation Amortization Depletion | $304,000 | $248,000 |
| Depreciation And Amortization | $304,000 | $248,000 |
| Depreciation | $304,000 | $248,000 |
| Net Income From Continuing Operations | $-63,913,000 | $-48,707,000 |
Fetched: 2026-07-15